CERA

Science and Research

CANBERRA: A Randomized, Double-Masked, 48-week, Parallel-Group, Placebo-Controlled, Proof-of-Concept Study To Investigate The Efficacy And Safety Of RG7774 In Patients With Diabetes Mellitus type 1 Or Type 2 With Treatment-Naïve Diabetic Retinopathy

This study investigates the efficacy and safety of RG7774 in patients with diabetes mellitus Type 1 or Type 2 with treatment-naive diabetic retinopathy (DR).

Overview

The study’s main purpose is to assess the safety, tolerability, and effect of oral administration of RG7774 on the severity of diabetic retinopathy (DR) in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) and good vision.

  • Principal Investigator
Associate Professor Sanj Wickremasinghe

Learn more

View this study on ClinicalTrials.gov

See the ClinicalTrials.gov database listing for more detailed information about this study.